Hudman Hoo, MD
Critical Care Medicine · St Petersburg, FLNPI 1396730339
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,700 of the $51,406 with a category attached, or 77.2%. GSK accounts for 76.9% of it on its own, with 47 other manufacturers making up the rest. Reporting peaked in 2020 at $21,322 and has fallen 93.2% since, to $1,460 in 2025. Among critical care medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 454 payments — averaging $113.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$40K
- Sanofi$2K
- Viiv Healthcare Company$2K
- AstraZeneca$1K
- Boehringer Ingelheim$794
- Insmed, Inc.$761
- plus $5K from 42 others
Across 67 payments — averaging $2080.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$54K
- GSK$41K
- Insmed, Inc.$38K
- Chiesi USA, Inc.$7K
What the payments were for
- Consulting fees$1,7903%
- Speaking & faculty fees$39,70077%
- Food & beverage$9,69619%
- Education$2200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$27,425
- ANORO ELLIPTA$10,800
- DUPIXENT$2,061
- UPTRAVI$122
- Da Vinci Surgical System$112
- FASENRA$104
- BEVESPI AEROSPHERE$104
- SYMBICORT$104
- FARXIGA$104
How this compares
$51,406 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 33 | $449,978 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 235 | $249,737 |
| ZemairaAlpha-1-Proteinase Inhibitor | 12 | $98,810 |
| Dupixent PenDupilumab | 12 | $53,123 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $20,447 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $20,052 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $19,908 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $15,545 |
| Spiriva RespimatTiotropium Bromide | 16 | $11,166 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $10,022 |
| BreynaBudesonide/Formoterol Fumarate | 35 | $9,526 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $9,474 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 127 | $4,043 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $1,877 |
| Ventolin HfaAlbuterol Sulfate | 16 | $1,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $318 | $449,97833 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $39,543 | $289,697288 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,153 | $25,01939 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $794 | $21,18930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in St Petersburg
- Vinny SamuelSt Petersburg$171K
- Ala AhmadSt Petersburg$62K
- Eric SchillingSt Petersburg$14K
- Warren AbelSt Petersburg$9K
- Louis GuzziOrlando$635K
- Fortune AlabiKissimmee$587K
- Debabrata BandyopadhyayTampa$398K
- Fred UmehKissimmee$371K
- Amit TandonWesley Chapel$338K
- Omid ZadOrlando$325K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.